No-Lab Life Insurance Underwriting: Is Fluidless the Future?

No lab life insurance underwriting has gone from a niche experiment to something carriers actually bet their books on. Five years ago, the idea of issuing a million-dollar term policy without drawing blood felt reckless to most chief underwriting officers. Today, the majority of individual life applications in the United States never touch a lab. The question is no longer whether fluidless underwriting works, but how far it can reach before hitting real actuarial limits.

"The percentage of applications qualifying for an accelerated path has increased from 42% in 2021 to 59% in 2025." --- Gen Re, U.S. Individual Life Next Gen Underwriting Survey (2025)

What fluidless underwriting actually replaces

Traditional life insurance underwriting required applicants to schedule a paramedical exam, often weeks after submitting an application. A nurse or technician would visit, draw blood, collect a urine sample, and record blood pressure and height/weight measurements. Those samples went to a lab, results came back in 5 to 10 business days, and only then could an underwriter begin the real assessment work.

Fluidless underwriting removes the lab entirely. Instead of biological fluid analysis, carriers pull from a constellation of electronic data sources to build a comparable risk picture. The swap looks roughly like this:

Evidence type	Traditional approach	Fluidless replacement
Cholesterol, glucose, liver function	Blood draw and lab panel	Prescription history (Rx databases), EHR data
Nicotine and drug use	Urine sample	Prescription records, MIB codes, application attestation
Blood pressure	Paramedical exam reading	Contactless camera-based measurement (rPPG), wearable data
HIV, Hepatitis	Blood serology	MIB check, claims history, EHR integration
Overall health snapshot	In-person exam	Digital health assessment, motor vehicle records, credit-based scores
Build and physical condition	Measured at exam	Self-reported with algorithmic validation

The important thing to understand is that fluidless does not mean evidence-free. Carriers replacing labs are pulling from 15 to 30 data sources per application, compared to the 3 to 5 sources a traditional workflow might use. What changes is the source of the evidence, not the volume of it.

Where adoption actually stands in 2026

Gen Re's surveys provide the most reliable industry-wide data on this shift. Their 2024 U.S. Individual Life Accelerated Underwriting Survey, covering carriers representing over 2 million paid policies and $827 billion in face amount, found that 82% of participating carriers had either fully or partially implemented accelerated underwriting workflows. The average time from application to final decision dropped to 5 days in accelerated paths versus 23 days in traditional full underwriting.

Their follow-up Next Gen Underwriting Survey in 2025 broke the numbers down further. Of all individual life applications processed in 2024, about 12% were eligible for a fully automated decisioning path where no human underwriter reviewed the case at all. Another 47% qualified for accelerated (but not fully automated) review. The remaining 41% still went through traditional underwriting, typically because the face amount exceeded program limits or the applicant's risk profile flagged something that required fluid evidence.

Pacific Life's 2026 Underwriting Outlook Survey, which polled more than 100 industry leaders, found that 45% of life insurance executives report AI is already part of routine underwriting workflows. Electronic health records were rated as the data source expected to have the greatest impact on underwriting over the next three years, ahead of prescription databases and behavioral data.

The placement rate question

One concern that followed fluidless programs from the beginning was whether removing labs would hurt placement rates. If underwriters lacked the data confidence to approve borderline cases, the whole efficiency gain could be offset by higher decline rates.

Gen Re's data suggests the opposite. Their 2024 survey reported an 86% placement rate for applications processed through automated workflows. That compares favorably to historical placement rates for traditional full underwriting, which typically run between 75% and 85% depending on the product and face amount. Carriers attribute part of the improvement to speed itself: applicants who receive a decision in hours or days are less likely to abandon the process than those waiting weeks for a paramedical appointment.

What data sources make fluidless possible

The shift away from labs was not a single technology breakthrough. It happened because several data ecosystems matured at roughly the same time.

Prescription history databases became the backbone of fluidless programs. Services like Milliman IntelliScript and ExamOne's ScriptCheck aggregate pharmacy benefit manager records to show what medications an applicant has been prescribed, when, and by whom. A statin prescription tells an underwriter about cholesterol management. An insulin prescription tells them about diabetes. The medication history often reveals conditions an applicant might not disclose on an application.

Electronic health records are the next frontier. As interoperability improves through FHIR-based APIs and health information exchanges, carriers can pull structured clinical data directly from provider systems. This includes lab results the applicant has already had done for routine medical care, making a separate insurance lab draw redundant for many applicants.

Motor vehicle records and credit-based insurance scores provide behavioral risk signals. The correlation between driving history and mortality risk has been well-documented in actuarial literature, and credit-based scores (where permitted by state regulation) add another dimension to the risk picture.

Contactless biometric measurement through remote photoplethysmography (rPPG) is an emerging data source that addresses one of fluidless underwriting's gaps. Camera-based vital sign capture can measure heart rate, heart rate variability, respiratory rate, and blood oxygen levels from a smartphone camera. This gives underwriters objective physiological data without requiring any equipment or in-person visit. Companies like Circadify are bringing this capability to the insurance market, allowing applicants to complete a health assessment from their phone in under a minute.

Where fluidless programs hit limits

Fluidless underwriting works well for a specific population: healthy applicants under age 60, applying for face amounts below $1 million to $3 million (depending on the carrier), with clean prescription histories and no recent hospitalizations. That population happens to represent the majority of term life applications, which is why the aggregate numbers look so strong.

The limits show up at the edges. High-net-worth policies above $5 million typically still require full evidence, including labs and attending physician statements. Applicants with complex medical histories, recent surgeries, or unusual medication profiles get knocked out of the accelerated path and into traditional review. Older applicants, particularly those over 65, are less likely to qualify because the actuarial value of fluid-based evidence increases with age as the base mortality rate rises.

Factor	Fluidless-friendly	Traditional still needed
Face amount	Under $1M--$3M	Above $3M--$5M
Age range	18--60	60+ (varies by carrier)
Medical history	Clean Rx, no recent hospitalizations	Complex conditions, recent surgery
Product type	Term, simplified whole life	Universal life, large permanent
Risk class eligibility	Preferred, standard	Substandard, table-rated

Some carriers are pushing these boundaries. A few have extended fluidless eligibility to face amounts up to $5 million for applicants under 45 with favorable data profiles. Others are experimenting with using rPPG-based vital signs and wearable data to extend fluidless paths to older applicants. But the expansion is incremental and backed by mortality studies comparing outcomes between fluidless and traditional cohorts.

The mortality experience question

The actuarial credibility of fluidless underwriting depends on whether policies issued without labs show comparable mortality experience to those issued with full evidence. This is the question that keeps chief actuaries cautious and reinsurers attentive.

Munich Re and Gen Re have both published analysis suggesting that early mortality experience for accelerated underwriting cohorts is tracking within expected ranges. Gen Re's 2024 survey noted that one-third of carriers made material changes to their programs in the preceding twelve months, often adjusting eligibility criteria based on emerging experience data. The fact that carriers are refining rather than retreating suggests the mortality picture is acceptable, even if it is still maturing.

The industry consensus, such as it exists, is that fluidless underwriting is actuarially sound for the populations where it is currently deployed. The open question is whether the data sources that replace labs are durable, meaning whether prescription databases, EHR access, and behavioral data will continue to provide comparable predictive power as the insured population ages and healthcare patterns shift.

Current research and evidence

Research into the specific data sources powering fluidless underwriting continues to build. A 2022 study published in the Journal of Clinical Monitoring and Computing demonstrated 96% agreement between remote photoplethysmography respiratory rate measurements and standard clinical methods across 963 patients in a hospital-based trial. This kind of validation work matters for carriers considering rPPG as a data input because it establishes the measurement accuracy that actuaries need to trust the data.

Separately, research published in npj Digital Medicine (Nature, 2023) examined the broader prospects of visual contactless physiological monitoring in clinical settings, finding that camera-based vital sign measurement is a viable path for non-invasive health assessment. While this research focused on clinical applications, the underlying technology is the same being adapted for insurance screening.

On the underwriting side, Damco Solutions reported that AI-powered underwriting has cut decision times from 5 days to 12.4 minutes for standard policies while maintaining a 99.3% accuracy rate in risk assessment. Pacific Life's 2026 survey found that the biggest barrier to further AI adoption was not technology performance but the shortage of underwriting talent capable of working alongside automated systems.

The future of no-lab underwriting

The trajectory points toward fluidless becoming the default rather than the exception. Gen Re's data shows the accelerated-eligible percentage has climbed steadily from 42% in 2021 to 59% in 2025. If that trend holds, the majority of all individual life applications will bypass labs entirely within a few years.

What will push the boundary further is the continued maturation of real-time biometric data. As rPPG measurement becomes more widely adopted and validated, carriers gain access to objective physiological data that partially replicates what a paramedical exam provides, but at zero cost, with zero scheduling friction, and in under a minute. That changes the economics of fluidless eligibility expansion, particularly for the age bands and face amounts where carriers currently still require labs.

The other driver is consumer expectation. Insurance applicants in 2026 expect the same speed they get from every other financial product. A life insurance purchase that requires a nurse visit and a three-week wait feels anachronistic when a mortgage can close digitally in days. Carriers that cannot offer a fast, fluidless path risk losing applicants to competitors that can. Pacific Life's survey found workforce shortage as the biggest concern among underwriting leaders, which only accelerates the push toward automated, fluidless workflows that require fewer human underwriters.

Frequently asked questions

Is no-lab life insurance less thorough than traditional underwriting?

Not necessarily. Fluidless underwriting replaces labs with a broader array of electronic data sources, often pulling from 15 to 30 data feeds per application. The evidence base is different but not smaller. Carriers monitor mortality experience closely to ensure fluidless cohorts perform within expected ranges.

What face amounts can be underwritten without labs?

Most carriers offer fluidless underwriting for face amounts up to $1 million to $3 million, depending on the applicant's age and risk profile. Some have extended eligibility to $5 million for younger applicants with clean data profiles. High-net-worth policies above those thresholds typically still require traditional evidence.

How do carriers verify health data without a blood test?

Carriers use prescription history databases, electronic health records, motor vehicle records, credit-based scores, MIB checks, and increasingly, camera-based contactless vital sign measurements through rPPG technology. These sources collectively provide a risk picture that, for most applicants, matches or exceeds what a single blood draw reveals.

Will labs ever be fully eliminated from life insurance underwriting?

Probably not for all cases. High face amount policies, complex medical histories, and older applicants may continue to require fluid evidence for actuarial reasons. But for the majority of standard term life applications, labs are already optional at many carriers, and the trend is moving toward making fluidless the default path.

The carriers adapting fastest to fluidless underwriting are those investing in richer data ecosystems, integrating EHRs, prescription databases, and emerging biometric technologies like contactless vital sign measurement. For a deeper look at the technology infrastructure behind this shift, see our analysis of digital underwriting architecture and how reinsurers evaluate digital health programs.